Macrogenics Inc logo

Macrogenics Inc

NEW
NAS:MGNX (USA)  
$ 1.26 -0.22 (-14.86%) 07:08 PM EST
At Loss
P/B:
0.68
Market Cap:
$ 79.49M
Enterprise V:
$ -84.71M
Volume:
1.84M
Avg Vol (2M):
710.76K
Trade In:
What is a stock summary page? Click here for an overview.
Volume:
1.84M
At Loss
Avg Vol (2M):
710.76K

Business Description

Description
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
Name Current Vs Industry Vs History
Cash-To-Debt 5.38
Equity-to-Asset 0.44
Debt-to-Equity 0.32
Debt-to-EBITDA -0.65
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -5.44
Distress
Grey
Safe
Beneish M-Score -1.68
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.92
Quick Ratio 3.92
Cash Ratio 3.63
Days Inventory 46.85
Days Sales Outstanding 18.13
Days Payable 201.8

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -0.8
Shareholder Yield % -0.84

Financials (Next Earnings Date:2025-05-09 Est.)

MGNX's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:MGNX

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Macrogenics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 148.339
EPS (TTM) ($) -1.08
Beta 1.43
3-Year Sharpe Ratio -0.02
3-Year Sortino Ratio -0.03
Volatility % 72.68
14-Day RSI 19.12
14-Day ATR ($) 0.17642
20-Day SMA ($) 2.0775
12-1 Month Momentum % -83.29
52-Week Range ($) 1.26 - 19.5408
Shares Outstanding (Mil) 63.09

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Macrogenics Inc Filings

Filing Date Document Date Form
No Filing Data

Macrogenics Inc Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Macrogenics Inc Frequently Asked Questions

What is Macrogenics Inc(MGNX)'s stock price today?
The current price of MGNX is $1.26. The 52 week high of MGNX is $19.54 and 52 week low is $1.26.
When is next earnings date of Macrogenics Inc(MGNX)?
The next earnings date of Macrogenics Inc(MGNX) is 2025-05-09 Est..
Does Macrogenics Inc(MGNX) pay dividends? If so, how much?
Macrogenics Inc(MGNX) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1